Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage Starts China Phase III Trial of Lead Drug for Acute Lymphoblastic Leukemia

publication date: Oct 20, 2023

Suzhou Ascentage Pharma  has dosed the first patient in a registrational China Phase III trial of its lead drug, olverembatinib, in patients with acute lymphoblastic leukemia. The regimen will administer olverembatinib plus chemotherapy compared to imatinib-chemotherapy in treatment-naïve patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). In 2021, olverembatinib, a BCR-ABL inhibitor, was approved for China use in patients with drug-resistant chronic myeloid leukemia. Ascentage believes olverembatinib could become the first tyrosine kinase inhibitor (TKI) approved in China for first-line treatment of Ph+ ALL. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital